169 related articles for article (PubMed ID: 33338057)
1. Adverse drug reactions associated with the use of biological agents.
Machado-Alba JE; Jiménez-Morales AL; Moran-Yela YC; Parrado-Fajardo IY; Valladales-Restrepo LF
PLoS One; 2020; 15(12):e0240276. PubMed ID: 33338057
[TBL] [Abstract][Full Text] [Related]
2. Adverse drug reactions in Colombian patients, 2007-2013: Analysis of population databases.
Machado-Alba JE; Londoño-Builes MJ; Echeverri-Cataño LF; Ochoa-Orozco SA
Biomedica; 2016 Mar; 36(1):59-66. PubMed ID: 27622439
[TBL] [Abstract][Full Text] [Related]
3. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
[TBL] [Abstract][Full Text] [Related]
4. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
[TBL] [Abstract][Full Text] [Related]
6. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
[TBL] [Abstract][Full Text] [Related]
7. Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital.
Khan LM; Al-Harthi SE; Saadah OI; Al-Amoudi AB; Sulaiman MI; Ibrahim IM
Saudi Med J; 2012 Aug; 33(8):863-8. PubMed ID: 22886119
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
9. Safety analysis of therapeutic drugs for breast cancer patients and construction of a predictive model for serious adverse drug reactions.
Lin S; Lei S; Liu W; Zhu X; Ren B; Feng B
Eur J Clin Pharmacol; 2024 Feb; 80(2):249-259. PubMed ID: 38099939
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
[TBL] [Abstract][Full Text] [Related]
11. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
Jose J; Rao PG
Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
Cliff-Eribo KO; Sammons H; Choonara I
Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
[TBL] [Abstract][Full Text] [Related]
15. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
[TBL] [Abstract][Full Text] [Related]
16. Patterns of adverse drug reactions in Jordan: a retrospective analysis of the National Pharmacovigilance Data Registry (2015-2021).
Mhaidat NM; Alshogran OY; Altawalbeh SM; Jaber JM; Banat HA; Ahmad DS; Alabsi W
Expert Opin Drug Saf; 2023; 22(10):957-965. PubMed ID: 37293991
[TBL] [Abstract][Full Text] [Related]
17. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
Castillon G; Salvo F; Moride Y
Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases.
van Lint JA; Jessurun NT; Hebing RCF; Hoentjen F; Tas SW; Vonkeman HE; van Doorn MBA; Sobels A; Spuls PI; van Puijenbroek EP; Nurmohamed MT; van den Bemt BJF
Drug Saf; 2020 Sep; 43(9):917-925. PubMed ID: 32451974
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a University Hospital in the Netherlands.
Dittrich ATM; Draaisma JMT; van Puijenbroek EP; Loo DMWMT
Paediatr Drugs; 2020 Aug; 22(4):425-432. PubMed ID: 32557243
[TBL] [Abstract][Full Text] [Related]
20. Developing an adverse drug reaction reporting system at a teaching hospital.
Baniasadi S; Fahimi F; Shalviri G
Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):408-11. PubMed ID: 18312492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
